Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs 10X Genomics Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.39, while 10X Genomics Inc trades at $67.59 (market cap $8.77B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| NVDL | TXG | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $67.29 |
52-Week Low | $21.76 | $11.34 |
Market Cap | — | $8.77B |
Enterprise Value | — | $8.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF has delivered 12.66% year-to-date returns through June 8, 2026, outperforming the S&P 500. Recent stock splits on June 25-26, 2026, adjusted the share structure.
The leveraged ETF offers amplified exposure to Nvidia's AI-driven growth but faces risks from daily reset mechanics and tracking divergence. With Nvidia continuing to beat earnings estimates and maintain AI leadership, NVDL provides tactical upside potential, though volatility compression and leverage decay remain significant concerns for long-term holders.
TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.
Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
